Can Fite Bio (CANF) AI Stock Analysis

• Market Cap: 51.22M
• Dividend Yield: N/A
• Average Volume (3M): 1.04M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.28
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IL
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 5,121,874,500
• 10 Day Avg. Volume: 130,742
• 30 Day Avg. Volume: 1,039,800
• PEG Ratio: 0.04
• Price to Book (P/B): 2.09
• Price to Sales (P/S): 16.84
• P/FCF Ratio: -1.48
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: 1.00 ▲(0.00% Upside)

The overall stock score reflects significant financial challenges, with declining revenues and negative profitability. Technical analysis reinforces the negative sentiment with bearish indicators. The absence of valuation metrics and earnings call data adds to the uncertainty. The company's financial instability is the most significant factor in the low score.

Can Fite Bio Business Overview & Revenue Model

Company Description

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

How the Company Makes Money

Can Fite BioPharma generates revenue primarily through licensing agreements, research and development collaborations, and milestone payments associated with the progression of its drug candidates. The company partners with pharmaceutical firms to co-develop and commercialize its products, receiving upfront payments and potential royalties on sales. Additionally, Can Fite may receive government grants or funding from health organizations aimed at supporting innovative medical research. These strategic partnerships and funding sources are crucial for sustaining its operations and advancing its clinical trials.

Can Fite Bio Financial Statement Overview

Summary

Can Fite Bio is experiencing declining revenues with significant operational losses as reflected by a negative net profit margin of -1169.58%. Despite a low debt-to-equity ratio, equity efficiency is declining. Cash flow remains under pressure with negative free cash flow, indicating financial instability and challenges in achieving profitability.

Income Statement

Can Fite Bio has been experiencing declining revenues, with a 9.28% decrease from 2023 to 2024. Despite maintaining a 100% gross profit margin due to negligible cost of goods sold, the company faces significant challenges with profitability, as indicated by a negative net profit margin of -1169.58% in 2024. The EBIT and EBITDA margins are deeply negative, reflecting ongoing operational losses. Overall, the income statement indicates substantial financial strain with limited revenue growth.

Balance Sheet

The company maintains a reasonable debt-to-equity ratio of 0.02, indicating low leverage. However, the equity ratio decreased from 2023 to 2024, standing at 59.62%, suggesting a decline in financial stability. The return on equity is significantly negative at -145.01%, highlighting unprofitability for shareholders. Despite low debt levels, the company's balance sheet reflects challenges in improving equity returns and asset efficiency.

Cash Flow

Can Fite Bio's cash flow remains under pressure with a negative free cash flow of -$7.64 million in 2024. The operating cash flow to net income ratio is 0.97, indicating cash losses align with net losses. Despite a free cash flow improvement from the previous year by 9.47%, the company struggles to generate positive cash flow, reflecting ongoing operational inefficiencies and cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	560.00K	674.00K	743.00K	810.00K	853.00K	763.00K
Gross Profit	560.00K	674.00K	743.00K	810.00K	853.00K	763.00K
EBITDA	-8.90M	-8.12M	-8.18M	-10.08M	-12.83M	-14.13M
Net Income	-8.80M	-7.88M	-7.63M	-10.17M	-12.60M	-14.44M
Balance Sheet
Total Assets	7.72M	9.12M	9.99M	9.28M	20.25M	9.52M
Cash, Cash Equivalents and Short-Term Investments	6.46M	7.89M	8.92M	7.98M	19.14M	8.34M
Total Debt	90.00K	104.00K	40.00K	62.00K	124.00K	67.00K
Total Liabilities	3.54M	3.68M	3.75M	4.81M	5.87M	3.45M
Stockholders Equity	4.18M	5.44M	6.24M	4.47M	14.38M	6.07M
Cash Flow
Free Cash Flow	-8.36M	-7.64M	-8.44M	-10.81M	-9.87M	-12.09M
Operating Cash Flow	-8.35M	-7.64M	-8.44M	-10.80M	-9.86M	-12.06M
Investing Cash Flow	-2.00K	1.50M	498.00K	9.50M	-14.51M	-26.00K
Financing Cash Flow	10.08M	6.71M	9.14M	0.00	20.46M	17.68M

Can Fite Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:CANF, the sentiment is Negative. The current price of 1 is below the 20-day moving average (MA) of 1.00, below the 50-day MA of 1.00, and below the 200-day MA of 1.48, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 27.69 is Positive, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:CANF.

Can Fite Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLRX	―	54.83M	-0.84	―	―	0.47%	78.22%
CANF	―	51.22M	―	―	―	―	―